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The potential of amphiliphilic chitosan formed by grafting octanoyl chains on the chitosan 
backbone for pulmonary delivery of levofloxacin has been studied. The success of polymer 
synthesis was confirmed using FT-IR and NMR, whilst antimicrobial activity was assessed 
against Pseudomonas aeruginosa.  Highly dispersible dry powders for delivery as aerosols were 
prepared with different amounts of chitosan and octanoyl chitosan to study the effect of 
hydrophobic modification and varying concentration of polymer on aerosolization of drug. 
Powders were prepared by spray-drying from an aqueous solution containing levofloxacin and 
chitosan/amphiphilic octanoyl chitosan. L-leucine was also used to assess its effect on 
aerosolization. Following spray-drying, the resultant powders were characterized using 
scanning electron microscopy, laser diffraction, dynamic light scattering, HPLC, differential 
scanning calorimetry, thermogravimetric analysis and X-ray powder diffraction. The in vitro 
aerosolization profile was determined using a Next Generation Impactor, whilst in-vitro anti-
microbial assessment was performed using MIC assay. Microparticles of chitosan have the 
property of mucoadhesion leading to potential increased residence time in the pulmonary 
mucus, making it important to test the toxicity of these formulations. In-vitro cytotoxicity 
evaluation using MTT assay was performed on A549 cell line to determine the toxicity of 
formulations and hence feasibility of use. The MTT assay confirmed that the polymers and the 
formulations were non-cytotoxic. Hydrophobically modifying chitosan showed significantly 
lower MIC (4 fold) than the commercial chitosan against Pseudomonas aeruginosa. The 
powders generated were of suitable aerodynamic size for inhalation having a mass median 
aerodynamic diameter less than 4.5 µm for formulations containing octanoyl chitosan. These 
highly dispersible powders have minimal moisture adsorption and hence an emitted dose of 
more than 90% and a fine particle fraction (FPF) of 52%. Powders with non-modified chitosan 
showed lower dispersibility, with an emitted dose of 72% and FPF of 20%, as a result of high 
moisture adsorption onto the chitosan matrix leading to cohesiveness and subsequently 
decreased dispersibility.  
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Pseudomonas aeruginosa. 
Introduction 
Chronic respiratory infections are difficult to eradicate leading to high rates of morbidity and 
mortality and high healthcare costs [1]. Lower respiratory tract infections (LRTIs) are 
responsible for the highest number of deaths in low-income countries, placing a considerable 
strain on their health economies [2]. LRTIs lead to 3.2 million deaths annually worldwide, 
accounting for 6.7% of the global disease burden, and they were the 3rd leading cause of death 
in 2011 [2]. A major concern with conventional antibiotic treatment of LRTIs is the requirement 
of  a high dose to be delivered for effective eradication of the organism [1]. Hence, in the past 
decade increasing attention has been given to developing systems for delivery of antibiotics by 
means of inhalation directly to the respiratory epithelium [3], [4].  
 
There are very few antibiotic formulations marketed for treatment of pulmonary infections, e.g. 
Tobramycin and Aztreonam inhalation solutions for nebulization. However, much research is 
being conducted into engineering inhalable antibiotic carrying nanoscale carriers such as 
liposomes [5], [6], polymeric nanoparticles [7], [8], solid lipid nanoparticles [9], [10] and 
polymer nanoparticle aggregate particles (PNAPs) [11], in particular to target the biofilm 
pulmonary infections associated with cystic fibrosis (CF) or chronic obstructive pulmonary 
disease (COPD).  
 
CF and COPD are characterized by the presence of a thick viscoelastic mucus layer which has 
mesh with average spacing of 100-400 nm, and is responsible for failure of many treatment 
modalities using the pulmonary route for local and systemic delivery [12], [13]. Pseudomonas 
aeruginosa has been reported to be the major causal pathogen associated with approximately 
80% of CF cases [14]. Another hindrance to antibiotic penetration is the bacterial generated 
multicellular surface associated biofilm composite of exopolymeric substances (EPS), such as 
polysaccharide, proteins and extracellular DNA which forms a strong, sticky network  housing 
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bacterial cells and serves as a barrier delaying penetration of antibiotics [14], [15]. 
Polymer/lipid nanoscale systems have been proposed to be more effective than conventional 
antibiotic formulations as they can penetrate the biofilm due to a decrease in direct 
interactions between EPS and antibiotic [12], [14]. Carrier-associated delivery of antibiotic also 
aids in decreasing the degradation caused by antibiotic-inactivating enzymes, such as β-
lactamase present in the biofilms secreted by Pseudomonas aeruginosa [14]. However, delivery 
of nanoparticle systems directly to the pulmonary region is problematic due to their instability 
resulting from particle-particle interaction, and poor deposition properties within the airways, 
resulting in loss during exhalation [16]. Tsapis et. al [17] have described a strategy whereby 
nanoparticles are incorporated into microscale structures, embracing the advantages of both 
nanoscale and micrometer-scale particles, enabling efficient delivery using a simple dry powder 
inhalation (DPI) system. Microparticles formed by aggregated nanoparticles of mass median 
aerodynamic diameter (MMAD) 1-5 µm, when inhaled, deposit efficiently in the peripheral lung 
at the site of pulmonary infection. Exposure to the humid/moist conditions of the lungs results 
in liberation of nanoparticles. On reaching the vicinity of the biofilm colonies, the 
matrix/polymer dissolves and releases the antibiotic leading to high localized exposure [18], 
[12]. 
 
Drugs employed in inhalation products require a size less than approximately 5 µm. This is 
usually achieved by micronization/jet milling [19]. Powders produced by such high energy 
processes exhibit strong inter-particulate attractions, leading to agglomeration. Moreover, 
micronization does not permit precise control of particle morphology, size distribution, particle 
density or surface composition leading to variations, and produces defects and/or amorphous 
regions on crystal surfaces, resulting in altered aerosolization properties and posing 
considerable formulation challenges [20], [21], [22]. This has led to alternative ways of 
controlling particle size distribution, particle porosity, surface roughness, particle density, etc. 
Spray-drying has emerged as an attractive, one-step technique for producing powders suitable 
for pulmonary delivery [23]. This method also provides potential for incorporating a wide range 
of excipients into the spray-drying feedstock, including dispersibility enhancers, such as L-
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leucine [4], [24], [25], [26]; drug-release modifiers, such as glyceryl behenate [27], 
hydroxypropyl cellulose [28] and poly lactic acid poly lactides [29], [30], providing a convenient 
means of manipulating the properties of the end product [31].  
Chitosan, a naturally occurring linear copolymer of β-(1→4)-2-acetamido-D-glucose and β-
(1→4)-2-amino-D-glucose processed by partial deacetylation of chitin has been extensively 
investigated for transmucosal drug delivery, for instance for pulmonary, nasal and vaginal 
mucosal administration [32], [33], [34] due to its low toxicity, biodegradation, biocompatibility, 
mucoadhesiveness and enhancement of transcellular permeation [4], [16], [30]. Additionally, 
the potential benefits of chitosan and its derivatives include: immune enhancing effects [35], 
hypercholesterolemic effects [36], antimicrobial properties and antitumor properties [37]. 
Furthermore, the highly reactive primary amino groups and primary/secondary hydroxyl groups 
of chitosan provide opportunities for derivatization [38], [39]. For instance, polymeric 
amphiphiles formed by hydrophobic modification of chitosan, following acylation using fatty 
acid chains, such as  stearoyl, octanoyl and palmitoyl,  have been widely investigated due to the 
potential of forming nanosized micelles for drug and gene delivery [40]. Acylated chitosan has 
also been proposed to possess anti-microbial properties against the gram-negative bacteria 
Pseudomonas aeruginosa and Escherichia coli, which are commonly associated with lung 
infections [41].   
 
Varied strategies have been employed to engineer particles with improved flowability and 
aerosolization of dry powders and subsequently powder performance. These include 
modification of particle surface [42], [43], porous low density particles [44] and inclusion of 
coarser carrier particles and excipients. Current excipients used for pulmonary delivery are 
confined to classes like sugars viz. lactose, trehalose, mannose etc. and amino acids viz. L-
leucine, trilecine phenylalanine etc. [45], [46]. These carrier/excipients help to reduce the 
interparticulate forces between drug molecules, alter density of particles, improve surface 
activity and subsequently reduce the dependence of FPF on flow rate and inhaler type hence 
improving aerosolization [46]. L-lecuine a hydrophobic amino acid in particular has been shown 
to possess the capability of migration to the surface of the particle droplet in the rapid 
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atomization phase of spray-drying hence preventing water from being entrapped onto the 
surface producing pitted particles on drying which have a reduced contact area and 
consequently reduced cohesion.However, previous studies have demonstrated that L-leucine 
enhances the growth of bacterial associated biofilms in Pseudomonas aeruginosa models and 
hence limiting its use in CF and COPD making it absolutely necessary to find a replacement 
dispersibility enhancer for dry powders [47]. None of the previous literature studies have 
shown the dispersibility enhancement effects of hydrophobcally modified chitosan. In this 
study, we have hydrophobically modified chitosan and investigated the effects on the 
aerosolization of the fluoroquinolone antibiotic levofloxacin, and the antimicrobial activity of 
polymer and formulations. It would be interesting to study the effect of hydrophobic 
modification of chitosan on the dispersibility of the dry powders as L-leucine that is a model 
dispersibility enhancer is a hydrophobic amino acid. These formulations, optimized for 
levofloxacin content, were prepared by spray-drying, and were investigated for their thermal, 
physicochemical, antimicrobial, aerosolization and toxicological properties in order to explore 
the potential of this formulation approach to enhancing the delivery of levofloxacin as a 
therapeutic inhalation aerosol for treatment of lung infections. 
 
1. Materials and methods 
2.1. Materials 
Levofloxacin ≥ 98.0% purity, octanoyl chloride 99% purity and L-leucine ≥ 98.0% purity were 
purchased from Sigma-Aldrich Life Sciences (Poole, UK); (1→4) 2-amino-2-deoxy-β-D-glucose 
(Chitooligosaccharide) 1-3K was purchased from Kitto Life Co. Ltd (Kyongki, Korea); 
Spectra/Por® pre-wetted dialysis tubing with Molecular Weight Cut off (MWCO) 1kDa; sodium 
bicarbonate 99.7% purity and HPLC grade methanol, absolute ethanol, acetonitrile, 
trifluoroacetic acid (TFA), acetone and chloroform were purchased from Fisher Scientific Ltd  
(Loughborough, UK).  
2.2. Synthesis of water soluble N,O-octanoyl chitosan 1-3K 
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N, O-octanoyl chitosan was synthesized as shown in Fig. 1. Chitosan oligosaccharide 1-3K (10.0 
g) was dispersed in 100 mL of methanol by drop-wise addition with magnetic stirring (multi-
position magnetic stirring, RO 10 power IKA WERKE, Germany). 20 mL octanoyl chloride mixed 
with 80 mL methanol was added drop-wise and allowed to react, with magnetic stirring, at 60 
°C for 30 min, after which it was stirred at room temperature for 10 h.  
The solution was poured into acetone and product precipitated. This precipitate was washed 
with acetone at 50-60°C and filtered through a Whatmann® qualitative 110 nm filter paper. The 
precipitate was then dissolved in water, and chloroform was added to remove traces of 
unreacted octanoyl chloride which fractionated into the chloroform layer. This was repeated 
three times to ensure the product was free from octanoyl chloride. The product was re-
precipitated from water at room temperature by addition of acetone, then dissolved in 
absolute ethanol to remove unreacted chitosan, after which it was rotary evaporated using Hei-
Vap (Heidolph Instruments, Gmbh, UK) at 80 °C under vacuum until a dry powder was obtained. 
This powder was then dissolved in water and dialyzed against deionized water at room 
temperature for 48 h using a Spectra/Por® dialysis tubing membrane with cut off of 1 kDa. The 
final product was obtained by re-precipitation from acetone. 
2.3. Characterization of N,O- octanoyl chitosan 1-3K 
2.3.1. Proton Nuclear Magnetic Resonance (1H-NMR) 
High resolution 1H-NMR was recorded on a Bruker AVANCE 500 spectrometer to confirm the 
macromolecular structure of native chitosan and octanoyl chitosan, and to ascertain the 
success of derivatization. The degree of deacetylation of native chitosan was also calculated as 
per the 1H-NMR spectra. The spectrum was obtained at 298 K using 16 1H scans per sample and 
at a resonance frequency of 500.13 MHz for 1H. The polymer solution was prepared at a 
concentration of 1% in Deuterium oxide (D2O) for acquiring the spectrum for chitosan, and d6-
dimethyl sulfoxide (d6-DMSO) for octanoyl chitosan. 
 
2.3.2. Fourier Transform Infrared Spectroscopy (FT-IR) 
FT-IR was performed to establish the chemical structure of the starting and synthesized 
polymer and hence determine the success of derivatization. FT-IR spectra were analyzed by 
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placing the sample on ATR of a Spectrum™ 100 spectrophotometer (PerkinElmer, UK) and 
scanning in the spectral region of 4000–6500 cm−1. 
2.3.3. X- Ray Powder Diffraction (XRPD): 
The long range order of the molecules and hence crystallinity of chitosan, octanoyl chitosan and 
spray-dried microparticles was determined at ambient temperature using wide angle X-ray 
diffraction with a 5th generation Rigaku Miniflex 600 X- ray powder diffractometer equipped 
with a 600 watt X-ray tube, a copper anode operating in reflectance mode at wavelength kα λ 
1.5418 Å, voltage of 40 kV and current 15 mA. Polymer samples were mounted perpendicular 
to the horizontal axis and then rotated to obtain a scanning range of 2-50° 2 theta at a step size 
of 0.010 °/min and step rate of 2 step/min at 25 °C and hence a scanning time of 24.05 min per 
sample. Spray-dried microparticles were mounted perpendicular to the horizontal axis and then 
rotated to obtain a scanning range of 2-70° 2 theta at a step size of 0.010 °/min and step rate of 
2 step/min at 25 °C and hence a scanning time of 32.5 min per sample. The relative long range 
order (crystallinity) v/s non-order (amorphous) was assessed by comparison of the data 
obtained by XRPD of native and acylated chitosan and spray-dried v/s physically mixed 
microparticles.  
2.3.4. In vitro antimicrobial assessment by MIC studies 
The minimum inhibitory concentrations (MICs) of water-soluble chitosan, octanoyl chitosan and 
microparticles were determined by the broth dilution method in 96-well microplates (BD 
biosciences Falcon™, UK). Three sensitive strains of P. aeruginosa were used for the experiment 
namely 10663, 8620 and 599. Briefly P. aeruginosa strains were grown in isosensitest broth 
(ISB) at 37 °C. Bacterial suspension was prepared in broth and diluted to obtain an optical 
density (OD) of 1 at 600 nm which corresponds to 1×108 CFU/mL of broth, after which a 200 X 
dilution with the same broth was performed to obtain 5×105 CFU/mL which was used in the 
determination of MIC. 
Aqueous solutions of polymers were prepared to obtain a standard concentration of 80 mg/mL 
chitosan.  Further dilutions were performed in broth to obtain concentrations ranging from 40 
mg/mL to 0.625 mg/mL in a final volume of 100 µL in each well by serial dilution. Standard 
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aqueous solutions of the drug levofloxacin and spray-dried powders were prepared as per the 
drug loading for each formulation to obtain a concentration of 64 µg/mL of levofloxacin. 
Further dilutions were performed in broth to obtain concentrations ranging from 32 to 0.006 
µg/mL in a final volume of 100 µL in each well. To these wells, 100 µL of the P.aeruginosa 
strains (5×105 CFU/mL concentration in ISB) were added and the plates then closed and packed 
into a plastic bag before incubation for 12 h at 37 °C. The MIC endpoints for all the tested 
materials were determined by visual inspection where no turbidity corresponded to inhibition 
of growth of organism. 
2.3.5. In vitro cell toxicity of polymers and spray-dried microparticles (MTT assay) 
The toxicity profiles of samples were evaluated over 24 h in adenocarcinomic human alveolar 
basal epithelial cell line, A549. The cells (passage no. 45-49) were cultured in 96-well plates with 
100 μL Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal 
bovine serum (FBS)/1% antibiotic/antimycotic solution (complete medium) for 24 h in a 
humidified 5% CO2/95% incubator at 37 °C. 100 μL of freshly prepared dispersions in the 
complete medium were added to the wells to achieve an appropriate concentration (0-5 
mg/mL; n=3), and 10% dimethyl sulfoxide (DMSO) was used as a positive control, and incubated 
for a further 24 h, followed by addition of 40 μg/mL MTT solution (5 mg/mL in PBS, pH 7.4) to 
each well. After further incubation for 2 h, the medium was carefully removed and any 
formazan crystals generated were solubilized with 100 μL DMSO. Thereafter, the optical density 
(OD) was measured at 570 nm (SpectraMAX 190, Molecular Devices). The relative cell viability 
(%) was then calculated using Equation 1): 
Cell viability (%) = 
𝐎𝐃 𝐨𝐟 𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬
𝐎𝐃 𝐨𝐟 𝐮𝐧𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬
 × 100   Equation 1 
 
 
2.4. Preparation of formulations 
2.4.1. Spray-dried powders 
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Formulations for spray-drying were prepared by dissolving individual compounds weighed 
accurately (SD was ±0.2mg) on a high accuracy analytical balance in deionized water, then 
mixing solutions of the drug, polymer and excipients together and spray-drying.The 
composition of the formulations is shown in Table 1. Levofloxacin raw material was spray-dried 
to serve as a control. The formulations were spray-dried using a lab-scale nano spray dryer 
Büchi B-90 (Büchi Labortechnik AG, Switzerland) equipped with a piezoelectrically driven 
droplet atomizing technology. The inlet temperature was 120 °C, with 100 % aspiration, pump 
flow rate 20 mL/h, gas flow rate 133 L/min, 5.5 µm mesh nozzle and instrument pressure 47 
mbar. Spray-dried powders were immediately transferred to a glass vial and kept in a 
desiccator to prevent crystallization. Spray-dried levofloxacin: octanoyl chitosan formulations 
were also stored at room temperature at ambient humidity to study the effect of moisture on 
the spray-dried powder. Each preparation was prepared 3 times and spray-dried to indicate the 
reproducibility of the preparations. 
 
2.4.2. Physical mixtures of powders 
Powder blends were prepared by physically mixing levofloxacin and the different excipients at 
the ratios outlined in Table 1, using a mortar and pestle for 15 min.  In vitro aerosolization 
studies and XRPD were performed on these samples alongside spray-dried powders. 
2.5. Characterization of spray-dried powder 
2.5.1. Spray drying yield, % yield and drug content 
The yield of the spray-dried powders was determined gravimetrically and calculated as a 
percentage of the initial weights of formulation components. The levofloxacin content of the 
powders was measured in triplicate using high performance liquid chromatography (HPLC) 
(section 2.5.5), and expressed as a percentage of nominal content using Equation 2. 
 
Percentage drug content = 
𝐃𝐫𝐮𝐠 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐨𝐟 𝐥𝐞𝐯𝐨𝐟𝐥𝐨𝐱𝐚𝐜𝐢𝐧 𝐨𝐛𝐭𝐚𝐢𝐧𝐞𝐝 𝐛𝐲 𝐇𝐏𝐋𝐂
𝐓𝐡𝐞𝐨𝐫𝐭𝐢𝐜𝐚𝐥 𝐝𝐫𝐮𝐠 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐨𝐟 𝐬𝐩𝐫𝐚𝐲−𝐝𝐫𝐢𝐞𝐝 𝐩𝐨𝐰𝐝𝐞𝐫




2.5.2. Particle size distribution and zeta potential measurements 
The volume median diameter (VMD) and the particle size distribution (PSD) for all the spray-
dried powders and the respective raw materials were determined using a Sympatec laser 
diffraction particle sizer (Sympatec Gmbh System-Partikel-Technik, Germany). A RODOS/L 
dispersing unit, equipped with a microdosing device ASPIROS/L was used. A feed rate of 50 
mm/s was applied and analysis was performed at varying pressures of 4 bar and 2 bar to ensure 
deagglomeration of powders. Six replicate readings were performed on a single sample and 
results were expressed as VMD and Span; a common dimensionless parameter used for the 
quantification of distribution width based on the 10th, 50th and 90th percentile of cumulative 
distribution calculated using equation: 
Span= 𝐃𝐯𝟗𝟎 − 𝐃𝐯𝟏𝟎 𝐃𝐯𝟓𝟎⁄     Equation 3 
 
The hydrodynamic diameter and zeta potential of the dispersions formed following dissolution 
of the spray-dried powders in deionized water were measured by dynamic light scattering (DLS) 
using the Malvern ZetaSizer Nano ZS (Malvern Instruments Inc., UK) using 0.5% (w/v) dispersion 
of the respective formulations at 25 °C. 
 
2.5.3. Crystallinity, thermal properties and water content of spray-dried powders: 
 
Differential scanning calorimetry (DSC) 
Thermal analysis was performed on accurately weighed 5 mg samples using hermetically sealed 
aluminium pans (Tzero pans), a Q series™ DSC autosampler and TA DSC Q2000 (TA instruments- 
Waters LLC, New Castle, DE, USA). The melting point (Tm) of samples was recorded under a 20 
mL/min dry nitrogen gas purge at a flow rate of 50 mL/min. The samples were heated at a rate 
of 20 °C/min from 20 °C to 200 °C. Calibration of the instrument was performed routinely using 
indium as the calibrant. At least three scans were performed to ensure reproducibility 
 
Thermogravimetric analysis (TGA) 
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Residual water content of spray-dried powders was performed using a Pyris 6 TGA (Perkin 
Elmer, Cambridgeshire, UK). 5 to 10 mg samples in open ceramic pans were placed on the 
balance and heated from 20 °C to 500 °C at a rate of 10 °C/min then held for 1 min at 500 °C. 
The moisture content of the samples was calculated from the weight change between 20 °C and 
130 °C. 
 
2.5.4. Scanning electron microscopy (SEM) 
The shape and surface morphology of the spray-dried powders was examined using scanning 
electron microscopy (SEM) (FEI Quanta 200F SEM; Eindhoven, Netherlands). Samples were 
prepared by placing a small amount of freshly prepared spray-dried powder on to 12.5 mm 
aluminum specimen pin stubs covered with double-sided adhesive black carbon tabs (Agor 
Scientific, UK) then sputter-coated with gold (Qu0rum Q150R; Quorum Technologies Ltd., 
Sussex, UK) prior to observation under SEM. 
 
2.5.5. High-performance liquid chromatography (HPLC)of levofloxacin 
Levofloxacin was quantified using reversed-phase HPLC (Agilent 1260 infinity series; Agilent 
Technologies UK Ltd., Berkshire, UK). 20 µL samples were run at room temperature with a 
mobile phase comprising 0.1% TFA in HPLC grade water at pH 2.0: HPLC grade acetonitrile 
(85:15) and flow rate 1 mL/min using a 15 cm × 4.6 mm, 5 μm Supelco C8 column (Supelco, 
Bellefonte, PA, USA) with UV detection at 294 nm. Levofloxacin was quantified by peak area 
measurements at a retention time of 6.25 min. A standard curve for levofloxacin was 
constructed before each sample analysis in triplicates. The standard curve was linear from 0.25 
- 16 µg/mL, and was used to derive the standard equation for calculation of concentration of 
levofloxacin in experimental samples. The limit of detection and limit of quantification of 
levofloxacin were calculated as per the International Conference on Harmonization guidelines 
using formulae [48]: 
LOD = 3.3 SD/s 
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LOQ = 10 SD/s                                                             Equation 4 
where SD is the standard deviation of the Y-intercept and s= slope of calibration curve 
2.6. In vitro aerosol analysis using the Next Generation Impactor (NGI) 
The aerosolization properties of the spray-dried formulations and physically mixed formulations 
were investigated using an NGI (Copley Scientific Ltd., Nottingham, UK). Powder aliquots (10 
mg) were loaded manually into size 3 HPMC capsules and placed into a Cyclohaler® 
(Pharmachemie, UK) that was attached to the NGI via a stainless steel USP throat. The capsule 
was pierced and the liberated powder drawn through the NGI at a flow rate of 60 L/min for 6 s, 
using a low capacity pump (Model LCP5; Copley Scientific Ltd., Nottingham, UK). Stages 1-7 of 
the NGI were coated with 1 % silicon oil (Sigma-Aldrich, UK) in N-hexane (Fisher scientific, 
Loughborough, UK) to prevent particle re-entrainment. A 75 mm terminal micro-orifice filter 
was placed on stage 8. Under these conditions, the effective cut-off diameters are as follows: 
Stage 1-8.06 µm; Stage 2-4.46 µm; Stage 3-2.26 µm; Stage 4-1.66 µm, Stage 5-0.94 µm; Stage 6-
0.55 µm; Stage 7-0.34 µm, with Stage 8 having a terminal filter (Copley Scientific, UK).  After 
aerosolization, each stage was rinsed with 10 ml of ultrapure water (HPLC grade) and the drug 
content was quantified by reversed-phase HPLC after diluting each stage to achieve appropriate 
concentration as per the linearity of the calibration curve. Each experiment was performed in 
triplicate. The particle size distribution of the spray-dried and physically mixed powders was 
compared determining fine particle fraction (FPF) calculated as the amount of drug deposited 
on stages 2-8 as a percentage of the total drug collected representative of the fraction of 
aerosolized particles having cut-off diameter lower than 5µm. Mass median aerodynamic 
diameter (MMAD) and geometric standard deviation (GSD) were also calculated from the plot 
of log cumulative mass percent deposited on each stage of the NGI versus the cut-off diameter 
of that stage. 
2.7. Statistical analysis 
The values obtained from different experiments were statistically compared to control spray-
dried powders by using One-way Analysis of Variance (ANOVA) and Tukey post-hoc test. A P 
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value of less than 0.05 was considered significant for all experiments. A significance level of P 
less than 0.02 has also been considered for a few experiments to show the high significance of 
the outcome of results. 
 
 
Results and discussion 
3.1. N,O- octanoyl chitosan 1-3K characteristics  
3.1.1 Synthesized polymer yields 
The yield of N, O-octanoyl chitosan obtained after synthesis as analyzed by gravimetry and 
expressed as a percentage was 72.5%.  
 
3.1.2 FT- IR analysis 
The FT-IR spectra for chitosan 1-3K and N, O-octanoyl chitosan 1-3K are shown in Fig.2. The 
spectrum for Chitosan 1-3K has characteristic absorption peaks at ca 1636 cm-1 attributed to 
carbonyl stretching of secondary amine (amide I band), at 1594.4 cm-1 indicative of the N-H 
bending vibrations of non-acylated 2-aminoglucose primary amine and 1540.4 cm-1 indicative of 
the N-H bending vibration of secondary amine (amide II band) i.e. 2-acetamidoglucose. The 
presence of both 2-aminoglucose and 2-acetamidoglucose units were confirmed by the 
presence of bands at 1636, 1594.4 and 1540.4 cm-1. 
On acylation of chitosan to form N, O-octanoyl chitosan, the vibrational band attributed to the 
free amino group of chitosan shifted to lower frequency and higher intensity at 1511 cm-1, 
attributed to formation of N-octanoyl and hence intermolecular hydrogen bonding between the 
carbonyl of the octanoyl group and the hydrophilic groups on the polymer backbone. C=O 
absorption by the octanoyl group is more defined and prominent, with increased intensity of 
the band at 1611 cm-1, compared to the band at 1636 cm-1 for non-modified chitosan. The 
increase in intensity and prominence of vibrational bands at 2885 cm-1 of octanoyl chitosan is 
attributed to absorption by the –CH2 chain of octanoyl substituted at the primary amine of 2-
aminoglucose. Furthermore, a relatively weak vibrational band was observed at 1748 cm-1 
indicative of O-acylation. FT-IR confirmed octanoylation of chitosan with more prominence of 
15 
 
N-octanoylation as compared to weak O-octanoylation and hence formation of N, O-octanoyl 
chitosan. 
3.1.3 1H-NMR (proton nuclear magnetic resonance) 
The 1H-NMR spectra of chitosan in D2O and N, O-octanoyl chitosan in d6-DMSO are shown in 
Fig.3 and Fig.4 respectively. The chemical shift at 1.9-2.1 ppm represents three protons (-NH-
CO-CH3) of N-acetyl glucosamine (GlcNAc). The chemical shifts of the non-anomeric protons 
connected to the ring skeleton of glucosyl residue having similar electron densities show a 
partially overlapping behaviour to produce a broad signal around 3.5-4.0 ppm. The –CH-OH, 
HOHC-CH-CH2 and –CH2-OH protons appear at around 3.75 ppm, whereas the chemical shifts of 
–CH-CH2 and CH2-OH appear at 3.59 ppm in both spectra. The anomeric protons of the chitosan 
backbone, due to their neighbouring glycosidic and ring oxygen, appear at higher chemical 
shifts compared to non-anomeric protons, i.e. around 2.8-3.2 ppm. The degree of deacetylation 
of commercial chitosan calculated from the 1H-NMR spectra was found to be 86.42%. 
Other than the native chitosan chemical shifts, the spectra of N, O-octanoyl chitosan has three 
peaks at chemical shifts 0.85, 1.25 and 1.8 ppm which confirms the success of acylation. The 
chemical shift seen at 0.85 ppm in the 1H-NMR spectrum of N, O-octanoyl chitosan (Fig.4) can 
be assigned to methyl protons –CH2-CH3 of the octanoyl group. This peak becomes more 
prominent  with an increase in degree of acylation [40], and hence the low intensity of the peak 
can be attributed to low substitution of the octanoyl groups onto the chitosan backbone. The 
chemical shift at 1.25 ppm can be attributed to the –CH2-CH3, and that appearing at 1.8 ppm to 
–CO-CH2-CH3 of the octanoyl groups. The peak at 1.8 ppm was seen to overlap with the peak of 
three methyl protons (-NH-CO-CH3) of N-acetyl glucosamine and gives a triplet. 
3.1.4 XRPD (X-ray powder diffraction) 
XRPD was performed to characterize the crystallographic structure of the polymers, raw 
materials, spray-dried microparticles and physically mixed powders. The XRPD diffractogram of 
chitosan (Fig.5) shows a broad diffusive halo at around 21° indicative of the amorphous nature 
of chitosan. The XRPD diffractogram of synthesized N, O-octanoyl chitosan  (Fig.5) shows a 
similar halo around the same 2Θ, however, the “hump” was seen to be split into two peaks as 
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encountered earlier in the literature, confirming the identity of successful derivatization [49]. It 
is assumed that the attachment of an octanoyl group onto the chitosan backbone leads to 
formation of sharper peaks with generation of new peaks at 19.6° and 25.71° which forms a 
more stable organization and hence enhances the stability of the polymer. XRPD analysis of 
spray-dried levofloxacin (Fig. 6) showed sharp diffraction peaks at 2Θ of 6.91, 10.0, 13.6, 16.35, 
20.08 and 26.93 characteristic of high degree of crystallinity of the drug. The diffraction pattern 
was similar to that produced by unprocessed raw material (Fig. 7). Spray-dried powders 
containing chitosan and octanoyl chitosan showed the presence of broad diffuse peaks 
indicative of the long range disorder and hence amorphous nature of the formulations (Fig. 6). 
However, formulations spray-dried without chitosan (levofloxacin: L-leucine (4:1)) showed 
narrow diffraction peaks indicative of crystalline nature of the powders.  Physical mixtures at 
the same molar mass as the spray-dried formulations (Fig. 7) showed narrow diffraction peaks, 
indicating that spray-drying in the presence of chitosan or hydrophobically-modified chitosan, 
leads to transformation of the powders into an amorphous state.  
3.1.5 In vitro antimicrobial activity of polymers and spray-dried microparticles 
MIC data for chitosan and synthesized N, O-octanoyl chitosan against three planktonic strains 
of P.aeruginosa namely 10663, 8620 and 599 are shown in Table 2. N, O-octanoyl chitosan 
showed a 4-fold decrease in MIC compared to non-modified chitosan, hence, showing higher 
anti-pseudomonal activity due to its increased hydrophobic character. Optimized levofloxacin 
spray-dried powders also possessed an in-vitro antibacterial activity (Table 2). Similar or a 1- 
fold less MIC was seen for the spray-dried powders with octanoyl chitosan, wherein, the slight 
decrease in MIC could be attributed to an additive anti-pseudomonal activity of octanoyl 
chitosan as shown in Table 2.. 
 
3.1.6 In vitro cytotoxicity of the polymers and spray-dried microparticles 
The MTT assay is a reliable method to test the cytotoxicity of polymers. Hence A549 lung 
epithelial cell viability was investigated by exposure to various concentrations of polymers 
within the range of 0-2.5 mg/mL (Fig. 8). Increasing the hydrophobicity of chitosan, by 
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derivatization did not significantly change (p<0.05) cytotoxicity to control non-modified 
chitosan. A cell viability of 86.71±13.20% and 83.39±11.24% was seen for chitosan and N, O-
octanoyl chitosan respectively at a concentration of 2.5 mg/ml, as compared to the positive 
control 10% DMSO which showed viability of only 7%. Hence, it can be deduced that the 
synthesized polymer was non-toxic and would be predicted to not cause harm to the lung 
epithelia under the conditions and timescale of this study.  The spray-dried formulations, i.e. spray-
dried levofloxacin: octanoyl chitosan: L-leucine (4:1:0.25) cell viability of 88.52%, spray-dried 
levofloxacin:octanoyl chitosan (4:1) cell viability of 91.7%, spray-dried levofloxacin:octanoyl chitosan 
(2:1) cell viability of 93.74% (not shown)  and spray-dried levofloxacin:octanoyl chitosan (1:1) cell 
viability of 85.93% (not shown) indicate that up to a concentrations of 0.3125 mg/mL formulations were 
well tolerated and not significantly different from that of spray-dried levofloxacin with a cell viability 
89.66% at a concentration of 0.3125 mg/mL (p<0.05; Fig. 9). However, the viability decreased at 1.25 
mg/mL concentrations but still showed survival greater than 50%. Consequently, it may be concluded 
that the spray-dried formulations, with potential for use as dry powders inhalations to treat pulmonary 
infections were non-toxic under the conditions and timescale of study. 
3.2 Spray-dried powder characteristics 
3.2.1 Drug content, % yield, size and size distribution 
With the innovative electrostatic collector of the Büchi B-90 nano spray dryer, yields in the 
range 51% to 79% of theoretical were produced, dependent on composition (Table 3), with 
formulations containing chitosan and hydrophobically-modified chitosan giving statistically 
greater yields (p < 0.02) than spray-dried levofloxacin alone, indicating better deposition of 
formulations containing chitosan in the electrostatic collector of the spray dryer. The limit of 
detection and quantification for levofloxacin using HPLC-UV were found to be 0.08 mcg and 
0.25 mcg respectively. The levofloxacin content of spray-dried powders, determined by HPLC, 
ranged from 77 to 118% of predicted amount (Table 3). Data for size distributions of the spray-
dried powders, which were unimodal, are shown in Table 3. The VMD for all the spray-dried 
powders was between 2.5 and 4.6 µm, i.e. of a size appropriate for ensuring gratest probability 
of delivery to the lungs. Following dispersion of powders in deionized water the size was found 
to be in the nanometric range as analyzed by the DLS with a small net positive charge indicative 
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of their formation of nanometric dispersion on exposure to the moist surrounding of the airway 
epithelium where they are deposited. 
 
3.2.2 Scanning electron microscopy (SEM) 
SEM micrographs of the spray-dried powders and raw materials are shown in Figure 10. 
Levofloxacin (Fig. 10A) comprised irregular, columnar, crystals having a wide size distribution. 
The columnar elongated shape presents a relatively large contact area between particles, likely 
to lead to cohesiveness and poor dispersibility. Spray-dried levofloxacin (Fig. 10B) comprised 
spherical particles with a relatively smooth surface and size in good agreement with that 
measured by laser diffraction (Table 3). Spherical particles have decreased contact area leading 
to decreased cohesiveness and better dispersibility and aerosolization [50], [51]. SEM 
micrographs of spray-dried powders of levofloxacin: octanoyl chitosan (Figs. 10C, 10D, 10E) and 
levofloxacin: chitosan (Fig. 10F, 10G, 10H) revealed spherical particles, but with a less smooth, 
corrugated surface morphology and diameters in good agreement with that measured by laser 
diffraction (Table 3). Corrugations on the surface may further decrease the contact area 
between particles, reducing cohesiveness and increasing dispersibility [52]. SEM micrographs of 
the spray-dried levofloxacin: L-leucine formulation (Fig 10I) which contains about 20%w/w L-
leucine, showed fractured, hollow-surfaced spheres, with curved plates of nanometric thickness 
which have been reported earlier by various authors. These have spaces which produce an 
open powder which may increase dispersibility of cohesive material by increasing median 
geometric diameter and subsequently decreasing particle density [51], [53], [54]. The 
levofloxacin: octanoyl chitosan: L-leucine (Fig. 10J) particles contain only 5% w/w L-leucine, and 
hollow surfaced curved plates are not evident. The spherical particles’ surfaces are deeply 
corrugated and have a size in good agreement with that measured by laser diffraction (table 3). 
Fig. 10K shows the effect of moisture on the morphology of the spray-dried powders containing 
octanoyl chitosan alone. Spray drying often produces amorphous particles, which in a humid 
environment may sorb water and recrystallize.  After 60 days storage at room temperature and 
ambient humidity there was no considerable change in morphology or evidence of a change in 
crystallinity of the powder, as has previously been reported for spray-dried powders of 
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terbutaline sulphate [4]. This suggests that octanoyl chitosan formulations have reasonable 
physical stability in ambient conditions. 
 
3.2.3 Amorphous nature of spray-dried powders 
Differential scanning calorimetry (DSC) 
The thermograms of levofloxacin and spray-dried powders containing octanoyl chitosan are 
shown in Fig. 11. The thermogram of levofloxacin showed a sharp endothermic peak with an 
onset at 120 °C, indicative of melting and hence demonstrating the crystalline nature of raw 
material, in agreement with XRPD data (Fig. 7). The DSC thermogram of spray-dried powders 
containing octanoyl chitosan did not show characteristic endotherms, indicating production of 
an amorphous form during spray drying. The production of an amorphous form may result in 
powders having a higher solubility and faster dissolution rates in lung fluids. Futhermore, 
exothermic transitions around 80-95°C was observed for the spray-dried powders which were 
not seen in the thermograms of the raw materials. This corresponds to the heat produced by 
the sample on phase transition indicative of recrystallization of spray-dried powders. 
1 
Thermogravimetric analysis (TGA) 2 
Mass loss as a function of temperature between 20-130 °C (Table 3) is indicative of the 3 
moisture content of the powders. TGA thermograms showed a statistically (p < 0.05) greater 4 
weight loss for spray-dried powders containing chitosan than for those containing 5 
hydrophobically-modified octanoyl chitosan and L-leucine. This weight loss can be attributed to 6 
greater adsorption of water in the matrix of the hydrophilic chitosan polymer chains, 7 
preventing its loss during spray-drying and resulting in higher final water content. Spray-dried 8 
octanoyl chitosan-containing powders showed similar (p>0.05) water loss as spray-dried 9 
levofloxacin powder, indicating minimal entrapment of water. Addition of octanoyl groups onto 10 
the chitosan backbone prevents hydrophilic moisture entrapment within the matrix leading to a 11 
drier final product. This may also result in a less cohesive powder with better flow properties 12 
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and subsequently improved aerodynamic properties and FPF compared to spray-dried 13 
formulations with chitosan.  14 
3.2.4 In-vitro aerosol properties  15 
The in-vitro aerodynamic behaviour of powder formulations delivered from a Cyclohaler into 16 
the NGI is shown in Figs. 12, 13 and 14, and the derived aerodynamic parameters are presented 17 
in Table 4.  18 
All powders were highly dispersible, with at least 71.62%  of the capsule contents being emitted 19 
during aerosolization, and giving a recovery of at least 75.7% levofloxacin from the NGI; within 20 
pharmacopoeial limits of 75-125%. For spray-dried levofloxacin, a high proportion of drug is 21 
deposited in the inhaler and throat region of the NGI (Fig. 12, 13). Spray-dried powders 22 
containing octanoyl chitosan produced the low deposition of levofloxacin in the inhaler and 23 
throat regions, with increased deposition particularly in stages 2 and 4 of the NGI, 24 
demonstrating the increased dispersibility of this formulation. The powders generated were of 25 
suitable aerodynamic size for inhalation having a mass median aerodynamic diameter (MMAD) 26 
less than 5 µm, with formulations containing octanoyl chitosan having MMADs less than 4.5 27 
µm. 28 
 29 
Spray-drying levofloxacin in the presence of octanoyl chitosan at different ratios increased the 30 
FPF by approximately 76% compared to spray-dried drug alone. Comparing the FPF of 31 
formulations incorporating the commonly used dispersibility enhancer L-leucine (Fig. 14; Table 32 
4), the FPF achieved with polymer octanoyl chitosan: L-leucine was significantly (p<0.05) higher 33 
than for a comparable spray-dried levofloxacin: L-leucine formulation. In addition, the FPF of 34 
spray-dried powders containing chitosan was significantly (p < 0.05) lower than spray-dried 35 
powders containing octanoyl chitosan (Table 4). This can be attributed to the higher moisture 36 
entrapment in the matrix of chitosan during spray-drying, leading to cohesiveness and hence a 37 
decrease in FPF of the spray-dried powders. Moreover, the amphiphilic nature of octanoyl 38 
chitosan means that during spray drying it is likely to migrate to the solution droplet/drying air 39 
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interface, resulting in modification of the surface properties and cohesive propertied of the 40 
powders. 41 
 42 
Previous research has demonstrated that a high content of dispersibility enhancers and carriers 43 
is required to increase effectively the aerodynamics of drugs delivered as powder aerosols [4], 44 
[55], [56]. The present study shows that increasing polymer concentration beyond 20% did not 45 
give any significant improvement in dispersibility, and hence formulations containing 20% 46 
octanoyl chitosan would be favorable for use, incorporating the maximum amount of antibiotic 47 
for delivery of a high localized dose of levofloxacin. The dispersibility of the formulations with 48 
octanoyl chitosan were comparable to those containing L-leucine, an established dispersibility 49 
enhancer for aerosol formulation, showing that the derivatized natural polymer, octanoyl 50 
chitosan, was a highly efficient dispersibility enhancer and hence is attractive for pulmonary 51 
delivery of other drugs. 52 
 53 
 54 
Powders comprising spray-dried levofloxacin: octanoyl chitosan and levofloxacin: octanoyl 55 
chitosan: L-leucine were compared with physical mixtures of the same composition. Both the 56 
physical mixtures showed deposition behaviour within the NGI comparable to levofloxacin raw 57 
material, with deposition high in the impactor. These formulations produced FPFs similar to raw 58 
material and significantly lower FPFs (p<0.05) than their spray-dried counterparts (Table 4). 59 
Thus, simple mixing of levofloxacin with octanoyl chitosan or L-leucine did not improve the 60 
deposition profile of levofloxacin. Consequently, formulating levofloxacin within a delivery 61 
system, such as octanoyl chitosan via spray drying such that components are included in 62 
individual, spherical particles is required.  63 
 64 
CONCLUSION 65 
The present investigation has shown that derivatization of chitosan with a hydrophobic 66 
octanoyl chain increased the in-vitro antimicrobial activity of the polymer. Moreover, spray-67 
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dried microparticles containing octanoyl chitosan showed a greater dispersibility and higher FPF 68 
when compared to those containing non-modified chitosan, demonstrating its suitability as an 69 
alternative natural inhalation aerosol dispersibility enhancer. Morphological investigation 70 
showed that the engineered particles have suitable aerodynamic particle size and relatively low 71 
physical contact due to the corrugations on their surface, leading to decreased density and 72 
hence high dispersibility.. Different ratios of polymer and levofloxacin were studied to explore 73 
the effect of increasing polymer concentration on aerosolization.  These spray-dried 74 
microparticles would be predicted to deposit predominately in the deep lung following 75 
inhalation where infections predominate, with minimal oropharyngeal deposition, thereby 76 
maximizing the dose delivered to the region of infection, increasing the efficiency of 77 
formulation and potentially reducing the occurrence of toxicity in the oropharyngeal region or 78 
following swallowing.  The dispersibility of spray-dried formulations containing octanoyl 79 
chitosan was comparable to those containing L-leucine, indicating its effectiveness as a 80 
dispersibility enhancer and suggesting its inclusion may be attractive for pulmonary delivery of 81 
other drugs. This natural polymer when hydrophobically modified would be attractive for its 82 
dispersibility enhancement property as compared to the model hydrophobic amino acid L-83 
leucine due to its antibacterial and mucoadhesive properties. Mucoadhesion would increase 84 
the residence time of the formulations in the lungs consequently enhancing the efficiency of 85 
antibiotic for treatment of infections. Biodegradability of this natural polymer and the non-86 
cytotoxicity determined by MTT assay suggests the likely safety of use of this polymer as 87 
dispersibility enhancer in formulations for aerosolization. 88 
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